US Pharmacy Groups Ask FDA To Allow Compounding OTC Pain Relief Doses
APhA, NCPA, APC make clear concerns about shortage of acetaminophen and ibuprofen in liquid formulations and their disappointment with FDA’s response in letter to Center for Drug Evaluation and Research.
You may also be interested in...
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.